Wuxi Biologics (Cayman) Stock Rallies 1.9% in Hong Kong

Dow Jones16:32

Citi: Fundamentals of China's healthcare industry continue to improve, with Hengrui Pharma and Wuxi Apptec as top picks.

Gelonghui, May 12 | Citi issued a research report stating that the past fiscal year and the first-quarter earnings season have confirmed a continued improvement in the fundamentals of China's healthcare industry, driven by innovative drugs and CDMO (Contract Development and Manufacturing Organizations). The domestic medical technology, services, and pharmacy sectors have bottomed out. Innovation is yielding returns, with upfront payments and milestone payments from licensing deals boosting profitability, accelerating sales of innovative drugs, and CXO (Contract Research and Manufacturing Outsourcing) order volumes reaching new highs. Looking ahead, the bank anticipates a series of short-term catalysts, including ASCO 2026 data releases, sustained momentum in licensing deals, and developments following April 14 pharmaceutical updates.

Gelonghui Finance10:26 · Ratings

Wuxi Biologics (Cayman) Stock Climbs 1.2% in Hong Kong

Dow JonesMay 11 16:33

Citi: The fundamentals of China's healthcare industry continue to improve, with Wuxi Apptec (02359.HK), Wuxi Bio (02269.HK), and Ali Health (00241.HK) as top picks.

Citi issued a research report stating that the past fiscal year and first-quarter earnings season have confirmed a continued improvement in the fundamentals of China's healthcare industry, driven by innovative drugs and CDMOs (Contract Development and Manufacturing Organizations). The domestic medical technology, services, and pharmacy sectors have bottomed out. Innovation is yielding returns, with upfront payments and milestone payments from licensing deals boosting profitability. Sales of innovative drugs are accelerating, while order volumes for CXOs (Contract Research and Manufacturing Organizations) have reached new historical highs. Looking ahead, the bank anticipates a series of short-term catalysts, including data releases at ASCO 2026, sustained momentum in licensing deals, and the aftermath of pharmaceutical pricing reforms announced on April 14.

AASTOCKSMay 11 12:48

Wuxi Biologics (Cayman) Stock Slips 2.5% in Hong Kong

Dow JonesMay 6 16:32

Wuxi Biologics (Cayman) Stock Slides 2.1% in Hong Kong

Dow JonesMay 5 16:31